Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma

NuklearMedizin

Volumn 42, Issue 6, 2003, Pages 240-243

  Löffler, Markus ^a   Weckesser, M ^a   Franzius, C ^a   Kies, P ^a   Schober, O ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Differentiated thyroid carcinoma; Iodine excretion; Levothyroxine; RhTSH; Thyroid hormone withdrawal

Indexed keywords

IODINE; IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEIODINATION; EXCRETION; FEMALE; FOLLOW UP; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RADIOISOTOPE THERAPY; THYROID CARCINOMA; THYROID SCINTISCANNING; THYROTROPIN BLOOD LEVEL; WHOLE BODY SCINTISCANNING;

EID: 0347134611     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625734     Document Type: Article

References (27)

1. Andersen S, Pedersen KM, Pedersen IB et al. Variations in urinary iodine excretion and thyroid function. A 1-year study in healthy men. Eur J Endocrinol 2001; 144: 461-5.
2. Dietlein M, Dressler J, Grunwald F et al. Guideline for in vivo and in vitro procedures for thyroid diseases (version 2). Nuklearmedizin 2003; 42: 109-15.
3. Haugen BR, Pacini F, Reiners C et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877-85.
4. Incerti C. Recombinant human thyroid-stimulating hormone (rhTSH): clinical development. J Endocrinol Invest 1999; 22: 8-16.
5. Ishizuki Y, Hirooka Y, Murata Y. Urinary iodide excretion in Japanese people and thyroid dysfunction. Nippon Naibunpi Gakkai Zasshi 1992; 68: 550-6.
6. Kogai T, Endo T, Saito T et al. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 1997; 138: 2227-32.
7. Ladenson PW, Braverman LE, Mazzaferri EL et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337: 888-96.
8. Lippi F, Capezzone M, Angelini F et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 2001; 144: 5-11.
9. Löffler M, Weckesser M, Franzius C et al. Exogenous stimulation by rhTSH in patients with differentiated thyroid carcinoma maintains elevated iodine excretion. J Nucl Med 2003; 44: 387P.
10. Luster M, Lassmann M, Haenscheid H et al. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2000; 85: 3640-5.
11. Luster M, Reinhardt W, Korber C et al. The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production. J Endocrinol Invest 2000; 23: 473-5.
12. Mariani G, Ferdeghini M, Augeri C et al. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother Radiopharm 2000; 15: 211-7.
13. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87: 1490-8.
14. McDougall IR, Weigel RJ. Recombinant human thyrotropin in the management of thyroid cancer. Curr Opin Oncol 2001; 13: 39-43.
15. Menzel C, Kranert WT, Dobert N et al. RhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half life of (131)I. J Nucl Med 2003; 44: 1065-8.
16. Morris LF, Wilder MS, Waxman AD et al. Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma. Thyroid 2001; 11: 749-55.
17. Pacini F, Molinaro E, Castagna MG et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87: 4063-8.
18. Pellegriti G, Scollo C, Giuffrida D et al. Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 2001; 11: 1025-30.
19. Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. J Endocrinol Invest 1999; 22: 30-4.
20. Petrich T, Borner AR, Weckesser E et al. Follow-up of differentiated thyroid cancer patients using rhTSH-preliminary results. Nuklearmedizin 2001; 40: 7-14.
21. Reiners C, Luster M, Lassmann M. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131. J Endocrinol Invest 1999; 22: 17-24.
22. Rendl J, Bier D, Reiners C. Methods for measuring iodine in urine and serum. Exp Clin Endocrinol Diabetes 1998; 106: S34-41.
23. Robbins RJ, Tuttle RM, Sharaf RN et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 619-25.
24. Torlontano M, Crocetti U, D'Aloiso L et al. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low risk patients with differentiated thyroid cancer. Eur J Endocrinol 2003; 148: 19-24.
25. Tsatsoulis A, Johnson EO, Andricula M et al. Thyroid autoimmunity is associated with higher urinary iodine concentrations in an iodine-deficient area of Northwestern Greece. Thyroid 1999; 9: 279-83.
26. Weber K, Wellner U, Voth E et al. Influence of stable iodine on the uptake of the thyroid - model versus experiment. Nuklearmedizin 2001; 40: 31-7.
27. Wellner U, Alef K, Schicha H. Influence of physiological and pharmacological amounts of iodine on the 131I uptake of the thyroid gland - a model calculation. Nuklearmedizin 1996; 35: 251-63.